Careers
Contact Us
Navigate Adaptimmune Limited
Home
Our Company
Overview
Board of Directors
Executive Committee
Partners
Scientific Advisory Board
Perspectives
Pipeline
Overview
ADP-A2M10 (MAGE-A10)
ADP-A2M4 (MAGE-A4)
ADP-A2AFP (AFP)
Technology
Overview
The Immune System
Our Engineered T-Cell Therapies
Our Technology Platform
Manufacturing
Intellectual Property
Publications
Patients & Families
Overview
Our Clinical Trials
Taking Part in our Clinical Trials
Clinical Trial FAQ
Cancer Information
Cancer Immunotherapy Month
Videos
News & Events
News
Scientific Conferences
Investor Conferences
Investors
Adaptimmune announces the start of SURPASS, our first Next-Generation Clinical Trial
Read More
Read about our latest collaboration with Alpine Immune Sciences to enhance our SPEAR T-cell anti-tumor responses
Click Here
You can find new videos about our SPEAR T-cells
Learn More
Explore stories from our colleagues and external experts on our science and how we're working to improve patient lives by transforming cancer treatment
Click Here
Focusing on the needs of our patients
Learn More
Enhancing the Affinity of T-cell to Fight Cancer
Learn More
Latest News •
View all
July 18, 2019
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
June 27, 2019
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
May 15, 2019
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
Adaptimmune on Linkedin
Adaptimmune on Twitter
Tweets by Adaptimmune
Clinical Trials
Our Pipeline
Manufacturing
Partnerships
Perspectives
